Recent Advances in the Evolving Treatment Landscape of Melanoma

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis

Long-Term Follow up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD Study